Effective method of treatment of porcine circovirus and lawsonia intracellularis infections

Abstract

The present invention relates to the use of porcine circovirus type 2 (PCV2) antigen and Lawsonia intracellularis (L. intracellularis) antigen for the prevention, reduction in severity of, lessening of the clinical symptoms associated therewith, reduced incidence in a herd, and treatment of swine against Porcine Circovirus Associated Diseases (PCVAD) and L. intracellularis associated diseases. In particular, the present invention provides a method for the treatment or prophylaxis of an animal against PCV2 infection and ileitis caused by L. intracellularis, or a method for reduction of clinical symptoms caused by or associated with a PCV2 and L. intracellularis infection, comprising the step of administering an effective amount of PCV2 antigen and L. intracellularis antigen to an animal in need of such treatment.

1 . A method for the treatment or prophylaxis of an animal against PCV2 infection and ileitis caused by  L. intracellularis , or a method for reduction of clinical symptoms caused by or associated with a PCV2 and  L. intracellularis  infection, comprising the step of administering an effective amount of PCV2 antigen and  L. intracellularis  antigen to an animal in need of such treatment. 
     
     
         2 . The method according to  claim 1 , wherein said animal is swine. 
     
     
         3 . The method according to  claim 1 , wherein said PCV2 antigen is an inactivated killed PCV2, modified life PCV2, or a subunit of PVC2. 
     
     
         4 . The method according to  claim 1 , wherein said PCV2 antigen is PCV2 ORF2. 
     
     
         5 . The method according to  claim 1 , wherein said PCV2 antigen is selected from the group consisting of Ingelvac® CircoFLEX™, CircoVac® CircoVent or Suvaxyn PCV2 One Dose®. 
     
     
         6 . The method according to  claim 5 , wherein said PCV2 antigen is Ingelvac® CircoFLEX™. 
     
     
         7 . The method according to  claim 1 , wherein said  L. intracellularis  antigen is a modified live  L. intracellularis.    
     
     
         8 . The method according to  claim 1 , wherein said  L. intracellularis  antigen is Enterisol® Ileitis or Enterisol® Ileitis B3903. 
     
     
         9 . The method according to  claim 1 , wherein said PCV2 antigen is Ingelvac® CircoFLEX™ and the  L. intracellularis  antigen is Enterisol® Ileitis or Enterisol® Ileitis B3903®. 
     
     
         10 . The method according to  claim 1 , wherein said  L. intracellularis  antigen is administered prior to the administration of said PCV2 antigen. 
     
     
         11 . The method according to  claim 1 , wherein said  L. intracellularis  antigen is administered at day one of age to week 12 of age. 
     
     
         12 . The method according to  claim 1 , wherein said PCV2 antigen is administered prior to the administration of said  L. intracellularis  antigen. 
     
     
         13 . The method according to  claim 1 , wherein said PCV2 antigen is administered at week 3 to week 12 of age. 
     
     
         14 . The method according to  claim 1 , wherein 2 to 20 days are in between the administration of both antigens. 
     
     
         15 . The method according to  claim 1 , further comprising the step of administering an immune stimulant. 
     
     
         16 . The method of  claim 1 , wherein prior to the administration of one or both antigens, the incidence of  L. intracellularis  and/or PCV2 is determined within a herd or farm. 
     
     
         17 . A kit of parts, comprising a container which comprises a PCV2 antigen, preferably Ingelvac® CircoFLEX™, a container which comprises  L. intracellularis  antigen, preferably Enterisol® Ileitis or Enterisol® Ileitis B3903, and an instruction manual, including the information for the administration of said PCV2 and  L. intracellularis  antigen. 
     
     
         18 . The kit of parts according to  claim 17 , wherein said container which comprises the PCV2 antigen and said container which comprises the  L. intracellularis  antigen are different containers. 
     
     
         19 . The kit of parts according to  claim 17 , wherein said instruction manual includes the information that the  L. intracellularis  antigen is administered prior to the administration of the PCV2 antigen. 
     
     
         20 . The kit of parts according to  claim 17 , wherein said instruction manual includes the information that the  L. intracellularis  antigen is administered at day one of age to week 12 of age. 
     
     
         21 . The kit of parts according to  claim 17 , wherein said instruction manual includes the information that the PCV2 antigen is administered prior to the administration of the  L. intracellularis  antigen. 
     
     
         22 . The kit of parts according to  claim 17 , wherein said instruction manual includes the information that 2 to 20 days are in between the administration of both antigens. 
     
     
         23 . The kit of parts according to  claim 17 , wherein said instruction letter includes the information that the PCV antigen is administered at week 3 of age to week 12 of age. 
     
     
         24 . The kit of parts according to  claim 17 , further comprising an immune stimulant and wherein said instruction manual includes the information that an immune stimulant is also administered. 
     
     
         25 . The kit of parts according to  claim 17 , wherein said instruction manual includes the information that the incidence of the  L. intracellularis  and/or PCV2 is determined within the farm or specific herd prior to administration of the antigens.